隨著中國經濟回暖，加之兩會期間釋放更多令人鼓舞的信號，更多穩健政策出臺，讓跨國公司在華發展信心更堅定。拜耳集團大中華區首席財務官烏爾里希·斯蒂弗表示，憑借龐大的市場規模、先進的工業體系、強大的供應鏈競爭力和不斷優化的營商環境，中國市場仍極具吸引力，拜耳等跨國企業在中國拓展業務、擴大投資的意愿強烈。
China's recovery, along with more encouraging signals and prudent policies introduced during the two sessions, is injecting greater confidence into multinationals operating in China, said a senior executive from Bayer.
拜耳公司一位高管表示，中國經濟正在復蘇，加之兩會期間釋放更多令人鼓舞的信號，更多穩健政策出臺，讓跨國公司在華發展信心更堅定。
Ulrich Stefer, chief financial officer of Bayer Group Greater China, said: "China, without any doubt, plays a crucial role in impacting global growth in 2023 as the world's second-largest economy. We noticed that various international financial institutions and investment banks increased their predictions for China's economic growth in 2023."
拜耳集團大中華區首席財務官烏爾里奇·史蒂夫表示：“毫無疑問，中國作為世界第二大經濟體，在影響2023年全球經濟增長方面發揮著關鍵作用。我們注意到，各國際金融機構和投行都上調了對2023年中國經濟增長的預測。”
He said that with the massive market size, sophisticated industrial system, strong supply chain competitiveness and the improving business environment, the Chinese market remains extremely attractive on a far-reaching level for multinational companies, including Bayer, to join and expand their investment.
他表示，憑借龐大的市場規模、先進的工業體系、強大的供應鏈競爭力和不斷優化的營商環境，中國市場仍極具吸引力，拜耳等跨國企業在中國拓展業務、擴大投資的意愿強烈。
"The multi-million euros expansion project of Bayer's Beijing Pharmaceuticals plant will be completed this year and it is expected to boost our prescription drug production capacities by 40 percent and largely enhance our capability to meet Chinese patients' medical needs," he said.
史蒂夫稱：“拜耳處方藥北京工廠產能提升項目將于今年完成。該項目投資數千萬歐元，預計將使拜耳處方藥生產能力提高40%，并大大提高拜耳滿足中國患者醫療需求的能力。”
Speaking of China's business environment, Stefer said: "Over the years, Bayer has witnessed China's substantial efforts to firmly improve the business environment for all kinds of enterprises."
談到中國的營商環境，史蒂夫表示：“多年來，拜耳見證了中國為堅定優化各類企業的營商環境的持續努力。”
"Particularly, the Foreign Investment Law and China's free trade zones have optimized China's law-based and open business environment for foreign companies, providing a solid basis for our in-depth participation and investment in this market," he said.
“特別是《中華人民共和國外商投資法》和自由貿易區優化法治化營商環境、服務外資企業，為拜耳深入參與和投資中國市場提供了堅實的基礎。”
In 2022, China increased the number of items in the Catalogue of Encouraged Industries for Foreign Investment to 1,474 from 987 in 2017. The number is expected to further increase with the publication of the 2023 catalogue.
今年1月1日正式生效施行的《鼓勵外商投資產業目錄（2022年版）》總條目從2017年的987個增加到1474個，預計條目數量將進一步增加。
"It opens up new areas and industry fields for foreign investment, such as advanced manufacturing, further unleashing the market potential and offering greater opportunities for foreign companies," Stefer said.
史蒂夫表示：“新版《鼓勵外商投資產業目錄》使外商投資企業進入的行業和領域擴大到先進制造業等新行業領域，此舉進一步釋放了市場潛力，為外企提供了更多機會。”
Data from the Ministry of Commerce showed that, ever since the Foreign Investment Law took effect in Jan 1 2020, 90 percent of the surveyed foreign enterprises held that the law was implemented well, and China's business environment was optimized.
商務部數據顯示，自《外商投資法》于2020年1月1日生效以來，九成受訪外企認為該法實施良好，中國的營商環境得到優化。
來源：中國日報網
編輯：董靜
掃碼下載
中文網微信